Jovine's Latest Biotech Pick Revealed

When Dylan Jovine releases a new biotech, it pays to act fast. Immunogen was taken over 33 days after he said it would for a 463% gain... [Wealth World News]( When Dylan Jovine releases a new biotech, it pays to act fast. Immunogen was taken over 33 days after he said it would for a 463% gain... We just sold Viking Therapeutics for a 273% gain... He sold Chemocentryx for a 300% gain... And, today I have some great news: He just released his [#1 Biotech for May.]( I urge you to get the details on his latest pick before it's too late. You'll discover: 1. How a $4 micro-cap beat the odds to win an FDA approval on a new kind of "Smart Chemo" that's like a heat-seeking missile against cancer. 2. Why the Journal Nature is calling it, "The Dawn of a New Era Against Cancer." 3. Why Big Pharma giants Pfizer, AbbVie, Merck and Johnson & Johnson put $60 billion into this treatment within the past 12 months. [Get the name of the stock here ]( Never before has so much money invested in a new cancer treatment so quickly. Morgan Stanley estimates the market is worth at least $140 billion. But right now, its stock price is just a tiny fraction of that size. [See why this $4 "Smart Chemo" stock can soar 300% (or more) ]( All the best, Simmy Adelman, Publisher Behind the Markets [Wealth World News] [Wealth World News]( This editorial email containing advertisements was sent to {EMAIL} because you subscribed to this service. To stop receiving these emails, unsubscribe]( Polaris Advertising welcomes your feedback and questions. But please note: The law prohibits us from giving personalized advice. To ensure our emails continue reaching your inbox, please add our email address to your address book. To contact Us, call toll free Domestic/International: +1 (302) 499-2858 Mon–Fri, 9am–5pm ET, or email us support@wealthworldnews.com. 124 Broadkill Rd 4 Milton, DE 19968[.]( Any reproduction, copying, or redistribution of our content, in whole or in part, is prohibited without written permission from Polaris Advertising. © 2024 Polaris Advertising. All rights reserved.